Systemic Adjuvant Treatment Recommendations and
Compliance in Australian Patients with Early Breast Cancer

Knowledge of current treatment uptake would allow an understanding of the level of compliance with national guidelines and allow an assessment of the potential role of OncotypeDX in Australia.

The primary objective of CEBAT was to evaluate the recommended additional treatments for women with early-stage breast cancer in Australia. The study focused on how well these recommendations were followed, based on the standards set by BreastSurgANZ, and also looked at how often patients did not follow the treatment plan.

Data was utilized from the Breast Quality Audit, which is a requirement for BreastSurgANZ members. Recommendations were examined for systemic treatments given to early breast cancer (EBC) patients.

The review included patients diagnosed between January 1, 2002, and December 30, 2016. Specifically looking at treatment suggestions for patients who shared similar characteristics with the eligible and recruited group in the TAILORx study. This helped us evaluate the potential usefulness of conducting this test for these patients.

Most Australian early breast cancer patients are receiving recommendations for additional systemic therapy based on the BreastSurgANZ KPIs. The patients also showed a high level of adherence to these treatment recommendations. This highlights the significance of collecting data and evaluating established benchmarks set by surgeons, even beyond just surgical results. It’s essential to delve into why some patients decline treatment, which calls for further research.